Arcutis logo.png
Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
May 06, 2021 08:30 ET | Arcutis Biotherapeutics, Inc.
Data show roflumilast produced robust efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of IGA success at eight weeksRoflumilast also demonstrated statistically...
Arcutis logo.png
Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update
May 04, 2021 16:51 ET | Arcutis Biotherapeutics, Inc.
New Drug Application (NDA) submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021Positive Phase 3 results for topical roflumilast...
Arcutis logo.png
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
May 03, 2021 16:09 ET | Arcutis Biotherapeutics, Inc.
Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical once-daily treatment for...
Arcutis logo.png
Arcutis to Present at the 2021 Truist Securities Life Sciences Summit
April 28, 2021 16:30 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis logo.png
Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021
April 23, 2021 10:01 ET | Arcutis Biotherapeutics, Inc.
Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentationData demonstrate roflumilast foam was well-tolerated and improved scalp...
Arcutis logo.png
Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)
April 19, 2021 09:05 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis logo.png
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
April 12, 2021 09:05 ET | Arcutis Biotherapeutics, Inc.
Roflumilast cream potential “Best in Class” topical PDE4 inhibitorAtopic dermatitis affects approximately 19 million patients in the U.S.The Company anticipates topline data in the second half of 2022...
Arcutis logo.png
Arcutis Announces Updates to its Executive Team
March 26, 2021 09:00 ET | Arcutis Biotherapeutics, Inc.
Scott Burrows to succeed John Smither as Chief Financial Officer (CFO) upon Mr. Smither’s retirementCorey Padovano named Vice President of SalesSean Brugger joins as Executive Director of Field...
Arcutis logo.png
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
March 18, 2021 09:05 ET | Arcutis Biotherapeutics, Inc.
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitorsTopline data anticipated second half 2023Vitiligo affects...
Arcutis logo.png
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021
March 17, 2021 16:05 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...